ABP 100
Alternative Names: ABP-100Latest Information Update: 28 Dec 2023
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Abpro Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Gastric cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Gastric-cancer in USA (Parenteral)